Skip to main
DBD
DBD logo

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 20%
Buy 30%
Hold 30%
Sell 0%
Strong Sell 20%

Bulls say

Diebold Nixdorf Inc. has demonstrated a strong ability to capture market share, gaining five percentage points globally in 2023, particularly in the U.S., Europe, and Latin America, indicating a positive trend in its competitive position despite slight losses in Asia. The company's strategic refinancing is projected to enhance free cash flow (FCF) generation significantly, with an anticipated $70 million annual improvement driving the FCF forecast to between 40% and 50% of EBITDA by 2025, up from 25% currently. Additionally, ongoing investments into manufacturing capabilities in India and the resilient demand in the global ATM and self-checkout markets suggest a favorable outlook for revenue growth as the installed base is expected to increase significantly over the next several years.

Bears say

Diebold Nixdorf Inc faces a negative outlook primarily due to declining demand for its products and increasing competition, which is exerting pressure on pricing and margins. The company is also grappling with disruptions in its supply chain, which could hinder product shipments, installations, and overall service delivery. Furthermore, there are concerns regarding liquidity and the company's failure to satisfy debt service obligations, compounded by foreign exchange volatility that affects its revenue generation in key markets such as EMEA and the Americas.

DBD has been analyzed by 10 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 30% recommend Buy, 30% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Hold based on their latest research and market trends.

According to 10 analysts, DBD has a Hold consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.